Vaccine Panel Scales Back COVID-19 Guidance and Alters Childhood Vaccine Policy

Action: On September 19, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) approved updated recommendations on immunizations, most notably shifting COVID-19 vaccination guidance to an “individual-based decision-making” approach and adopting new recommendations on the Hepatitis B and Measles, Mumps, Rubella, Varicella (MMRV) vaccines.  The recommendations signal a recalibration of Federal vaccine policy that could affect coverage requirements for health plans and vaccination uptake among the public.

Trusted Insights for What’s Ahead^®

• The ACIP, with a reconstituted membership, shifted from recommending routine COVID-19 booster vaccination for all adults to an “individual-based decision-making” approach. Also known as “shared clinical decision-making,” CDC characterizes this as a “decision process” between the health care provider and the patient or parent/guardian.
• In addition to this approach, for individuals from 6 months to 64 years, the ACIP emphasized that immunization decisions should consider that benefits are “most favorable for individuals who are at an increased risk for severe COVID-19 diseases” based on the CDC’s list of risk factors. Committee members narrowly rejected a proposal that would have state and local jurisdictions require a prescription for administration of a COVID-19 vaccine.
• The committee also voted to end recommending the combined MMRV vaccine for children under 4, now directing providers to administer separate MMR and varicella doses instead. Additionally, the panel postponed a vote on delaying the Hepatitis B birth dose, citing the need for more data to refine the recommendation.  
• Some states have begun to coordinate on vaccine recommendations in response to shifting Federal policy. Governors announced the West Coast Health Alliance on September 3, releasing its own vaccine guidelines that maintain broader guidance for COVID-19 more aligned with the previous CDC guidance. Similarly, several governors announced the Northeast Public Health Collaborative to improve coordination, build capacity, and “promote evidence-based public health across jurisdictions.”
• In response to the draft agenda for the meeting, AHIP, a leading trade association for American health insurance companies whose members serve over 200 million Americans, issued a statement that its members have voluntarily pledged to cover “all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing for patients through the end of 2026”—essentially reaffirming their current policies and likely blunting somewhat the impact of the new ACIP recommendations.
• The American Academy of Pediatrics and American Medical Association criticized the new recommendations for undermining vaccine confidence and reaffirmed their immunization schedules.